
The CEO denies that money should be involved in the settlement agreement with one of the company’s biggest generics rivals. But whether other types of assets have been transferred between the companies, he refuses to comment on.
Last week MedWatch revealed the secret settlement agreement between the two companies. The agreement effectively suspends all current court disputes involving Lundbeck and Teva, or any of its subsidiaries, and protects the Danish companies blockbuster-drug Cipralex from patent law suits.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app